• Dangerous games

    Employers' body Neasa is playing a potentially dangerous game, says Terry Bell.

  • Rational thinking

    All players should first consider the net result of their actions, says Leopold Scholtz.

  • Telkom's property poser

    BEE may be hindering Telkom's plans to offload redundant real estate, says Gugu Lourie.

Data provided by iNet BFA
See More

Merck in $688m settlement

Feb 14 2013 16:52 Reuters

Related Articles

Big Pharma helps tackle neglected diseases

Merck sells local unit

Adcock teams up with Germany's Merck

Adcock seeks more partnerships

Adcock concludes India acquisition

Drug firms win R2.5bn tender

New York - Merck on Thursday said it has agreed to pay $688m to settle two US investor lawsuits over disclosures of the results of a clinical trial involving the anti-cholesterol drug Vytorin.

The lawsuits alleged that Merck and Schering-Plough knew far in advance that the trial was a failure, but withheld that information from investors.

The trial, known as Enhance, had sought to demonstrate that Vytorin, a combination drug marketed by the two companies, was more effective than a competing drug in combating plaque build-up on artery walls.

The companies announced in January 2008 that Vytorin did not stop plaque any better than an inexpensive statin, Zocor, in high-risk patients with an inherited form of heart disease, though it did significantly reduce cholesterol levels.

Investors claimed they lost money in both companies' securities after results of the clinical trial were published.

Merck and Schering-Plough merged in November 2009.

The plaintiffs' law firms, Bernstein Litowitz Berger & Grossmann and Labaton Sucharow, said the combined settlements are among the 10 largest in a securities class-action case that did not involve a restatement of results.

In a statement, Merck said it will pay $215m to settle a lawsuit brought against Merck defendants, and $473m to settle a lawsuit against Schering-Plough defendants.

Both settlements require court approval.

Merck said it has recorded a $493m after-tax charge for the settlements. It said this reduced previously reported fourth-quarter profit per share to 30 cents from 46 cents.

Shares of Merck closed Wednesday at $41.15 on the New York Stock Exchange.

Follow Fin24 on Twitter, Facebook, Google+ and Pinterest.

merck  |  lawsuits

AstraZeneca raises forecasts

2014-07-31 12:19


Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Add your comment
Comment 0 characters remaining

Company Snapshot

We're talking about:

Small Business

A cash flow crunch often occurs in small businesses trying to balance cash coming in with cash going out. Watch this video to help you improve.

No need to keep up with the Joneses

Fin24 users provide their own personal tips on how to save money instead of trying to keep up with the Joneses.


Start saving...

Where can you stash your cash?
Time the key for retirement saving
Dummy's guide to saving
Save money with affordable account

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...